Jci_page_head_homepage_01 Jci_page_head_homepage_02
Cheryl J. Park, Zhen Zhao, Christine Glidewell-Kenney, Milos Lazic, Pierre Chambon, Andrée Krust, Jeffrey Weiss, Deborah J. Clegg, Andrea Dunaif, J. Larry Jameson, Jon E. Levine
Published in Volume 121, Issue 2
J Clin Invest. 2011; 121(2):604–612 doi:10.1172/JCI41702
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4
E2 does not induce pAkt immunoreactivity in the ARC, but activates it in the vlVMN.

(A) Representative image of EB-induced pAkt immunoreactivity in the ARC of Erα+/+, Erα–/–, and Erα–/AA mice 1 hour after vehicle or EB injection. Scale bar: 100 μm. (B) There was no difference in the number of E2-induced pAkt-ir cells in the ARC of Erα+/+, Erα–/–, and Erα–/AA mice. (C) Representative image of E2-induced pAkt immunoreactivity in the vlVMN of Erα+/+, Erα–/–, and Erα–/AA mice 1 hour after vehicle or EB injection. Scale bar: 100 μm. (D) E2 significantly increased the number of pAkt-ir cells in the vlVMN of Erα+/+ and Erα–/AA mice, but not Erα–/– mice (*P < 0.05, **P < 0.01 versus vehicle; n = 5–8).